OneMedNet's Data Milestone Signals Key Win in AI Healthcare Race

MINNEAPOLIS, MN – January 16, 2026 – OneMedNet Corporation (Nasdaq: ONMD) has successfully delivered a massive trove of anonymized healthcare data, representing 1.5 million patients, to a premier data analytics organization, a move that validates its technology and underpins a critical strategic pivot for the company. The delivery, consisting of over 1.49 billion individual data points across 4 million patient encounters, provides a crucial proof-of-concept for OneMedNet's new subscription-based business model, which it hopes will drive sustainable growth in the fiercely competitive healthcare data market.

This landmark transaction is more than just a large data transfer; it represents a key test for the recipient's platform, confirming its ability to ingest and operationalize the kind of complex, multimodal Real-World Data (RWD) that is becoming the lifeblood of modern drug discovery and AI development. For OneMedNet, it's a vital signal to investors and the market that its high-stakes bet on becoming a go-to provider of regulatory-grade, AI-ready data is beginning to pay off.

A High-Stakes Pivot to Recurring Revenue

The delivery comes at a pivotal moment for OneMedNet. The company is in the midst of a challenging financial transition, deliberately winding down its legacy BEAM platform to focus exclusively on its iRWD™ network and subscription sales. Recent financial reports reflect this difficult phase, with total revenue for the third quarter of 2025 standing at a modest $177,000 and the company reporting an operating loss of $2.24 million. The subscription revenue column for that period was notably zero, highlighting the pressure on the company to convert its pipeline into tangible, recurring income.

This successful delivery to a major, albeit unnamed, client is the first major validation of this new strategy. By shifting from one-time transactional sales to a subscription model, OneMedNet aims to build predictable annual recurring revenue (ARR) streams. This model provides clients with continuous, on-demand access to refreshed RWD, fostering long-term partnerships that are more deeply integrated into their workflows.

“Life sciences and data platform partners require Real-World Data at scale and sufficiently rich to capture real clinical complexity,” said Aaron Green, CEO and President of OneMedNet, in a statement. “Delivering a 1.5M patient, multimodal dataset under our subscription model demonstrates our ability to support enterprise validation today while advancing subscription-based data feeds that create durable, long-term value.”

This strategy is designed to create "satisfied subscription customers," as Green noted, which is essential for building shareholder value and achieving financial stability after a period of strategic investment and operational losses.

The Power of Multimodal Data and AI Infrastructure

The true value of the delivered dataset lies not just in its size, but in its depth and complexity. Described as "multimodal," the data integrates the full patient journey, combining structured information like lab results and medication lists with unstructured data such as practitioner notes and observations. This level of clinical fidelity is what separates standard data from the regulatory-grade RWD required for advanced analytics, AI model training, and submissions to bodies like the FDA.

Powering this capability is OneMedNet's strategic partnership with Palantir Technologies. The iRWD™ platform is built on Palantir's AIP Foundry, a sophisticated software infrastructure renowned for its ability to unify disparate, complex datasets and enable real-time insights securely. For healthcare, this is a critical advantage. The platform allows OneMedNet to ingest data from its network of over 2,130 healthcare sites, apply its proprietary AI algorithms to de-identify the information in compliance with HIPAA, and harmonize it into a standardized, queryable format.

This integration with Palantir is designed to dramatically reduce data inquiry response times from days to minutes, allowing life sciences clients to create custom data cohorts for research with unprecedented speed. Furthermore, the platform incorporates essential healthcare coding standards like SNOMED and ICD-10, making the data immediately useful for clinical and operational research without extensive pre-processing.

Navigating a Competitive Data Gold Rush

OneMedNet is carving out its niche in a market dominated by established giants and nimble specialists. The Real-World Evidence (RWE) solutions space includes major players like IQVIA, which offers vast, integrated health databases, and oncology-focused powerhouse Flatiron Health, known for its deep, curated data extracted directly from electronic health records. Other significant competitors include TriNetX, Komodo Health, and Aetion, each with its own unique approach to mapping and analyzing patient data.

In this crowded field, OneMedNet's differentiation hinges on its ability to deliver AI-ready, multimodal data at scale, powered by the robust Palantir infrastructure. While competitors also leverage AI, OneMedNet's focus on integrating unstructured data like physician notes with structured records and medical imaging offers a more holistic view of the patient. This comprehensive data is particularly valuable for training sophisticated AI models that can identify novel biomarkers, predict disease progression, or optimize clinical trial design.

The successful delivery of the 1.5 million-patient dataset serves as a powerful demonstration of this capability, proving that the company can handle the technical and regulatory complexities of providing such rich data while maintaining patient anonymity and data integrity.

Fueling a Multi-Billion Dollar Market

The demand for the exact type of data OneMedNet provides is exploding. The global market for RWE solutions was valued at over $2.2 billion in 2025 and is projected to more than double to $4.5 billion by 2030. This growth is mirrored in the AI for drug discovery market, which some analysts predict could soar from around $20 billion in 2025 to over $160 billion by 2035.

Pharmaceutical, biotechnology, and medical device companies are driving this demand as they race to reduce the staggering cost and time required to bring new therapies to market. High-quality RWD allows them to design more efficient clinical trials, identify patient populations for rare diseases, monitor post-market safety more effectively, and gain regulatory approval for new drug indications. Regulatory bodies like the FDA are increasingly embracing RWE, further legitimizing its use in critical decision-making.

By providing a clean, regulatory-grade, and AI-ready data feed, OneMedNet is positioning itself as a key enabler of this industry-wide transformation. This month's delivery is not just a commercial transaction but a significant contribution to the infrastructure that will power the next generation of data-driven healthcare innovation. With this validation complete, the company is better positioned to capitalize on its pipeline and expand its ecosystem, turning its strategic vision into sustained financial performance.